In patients with HER2-positive metastatic breast cancer, neratinib has been shown to have intracranial activity [31] and treatment with this drug significantly reduced the risk of HER2-positive breast cancer progression and delayed the spread of this type of cancer to the brain [32]. This evidence concerns the gene ERBB2 and breast carcinoma.